Diabetes Drug Dapagliflozin Increases Risk of Breast and Bladder Cancers

by Kathy Jones on  June 27, 2011 at 8:02 PM Drug News
RSS Email Print This Page Comment
A two-year study on the new diabetes pill being developed by Bristol-Meyers and AstraZeneca was found to increase the risk of breast and bladder cancers though the drug was effective.
 Diabetes Drug Dapagliflozin Increases Risk of Breast and Bladder Cancers
Diabetes Drug Dapagliflozin Increases Risk of Breast and Bladder Cancers
Advertisement

According to AstraZeneca's Elisabeth Bjork, around 1.4 percent of those who were taking the drug, known as dapagliflozin, developed some form of cancer compared to 1.3 percent of those who did not take the drug during the study.

Advertisement
Analysts have pegged the annual sales of dapagliflozin to be over $631 million by 2015 but rejection of the drug by the Food and Drug Administration could cut the earnings of the companies by 3 to 6 percent.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Diabetic Retinopathy Drug Toxicity Diabetes Diabetic Diet Mastitis Diabetes - Essentials Diabetes - Self-Monitoring of Blood Glucose (SMBG) Insulin Delivery Devices Diabetes and Exercise Vesico-Ureteric Reflux Causing UTI in Children 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive